CG Oncology(US:CGON) ZACKS·2025-11-14 15:11分组1 - CG Oncology, Inc. reported a quarterly loss of $0.57 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.30 per share a year ago [1] - The company posted revenues of $1.67 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 412.62%, and up from $0.04 million year-over-year [2] - CG Oncology's shares have increased approximately 31.7% since the beginning of the year, outperforming the S&P 500's gain of 14.6% [3] 分组2 - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend for estimate revisions for CG Oncology was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.59 on revenues of $3.37 million, and for the current fiscal year, it is -$2.15 on revenues of $2.74 million [7] 分组3 - The Medical - Biomedical and Genetics industry, to which CG Oncology belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]